Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia

Molecular Neurobiology
Marc Fakhoury

Abstract

The endocannabinoid system (ECS) is a group of neuromodulatory lipids, enzymes, and receptors involved in numerous behavioral and physiological processes such as mood, memory, and appetite. Recently, longitudinal and postmortem studies have shown that the ECS might be involved in neuropsychiatric disorders like schizophrenia. However, despite the large amount of research, our knowledge of the ECS and its implication in this debilitating disorder is still largely limited. This review aims at providing a comprehensive overview of the current state of knowledge of the ECS in schizophrenia and presenting some potential antipsychotic compounds that modulate this system. Findings from animal and human studies, and their implications for pharmacotherapy, will be integrated and discussed in this paper. A closer look will be given at the roles of the cannabinoid receptors type 1 (CB1) and type 2 (CB2), as well as the endogenous ligand N-arachidonoylethanolamine (AEA) and 2-arachidonylglycerol (2-AG), in the development of psychotic and schizophrenia-like symptoms.

References

Aug 1, 1990·The Journal of Nervous and Mental Disease·A Y Tien, J C Anthony
Oct 4, 1995·Biochemical and Biophysical Research Communications·T SugiuraK Waku
Sep 29, 1999·Neuroreport·F M LewekeD Piomelli
Jun 8, 2002·Prostaglandins, Leukotrienes, and Essential Fatty Acids·T SugiuraK Waku
Aug 16, 2002·American Journal of Epidemiology·J van OsH Verdoux
Oct 31, 2002·Psychopharmacology·Renee S MartinDavid A Lowe
Nov 26, 2002·BMJ : British Medical Journal·Louise ArseneaultTerrie E Moffitt
Jan 23, 2003·Psychological Medicine·D M FergussonN R Swain-Campbell
Sep 13, 2003·Lipids in Health and Disease·Nicola De MarchiVincenzo Di Marzo
Jan 13, 2004·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Miriam MelisGian Luigi Gessa
Jan 31, 2004·Progress in Neuro-psychopharmacology & Biological Psychiatry·Katerina ZavitsanouXu Feng Huang
Mar 12, 2004·Primary Care Companion to the Journal of Clinical Psychiatry·Raphael J. Leo, Paula Del Regno
Apr 17, 2004·Psychopharmacology·Emilio Fernandez-Espejo, Beatriz Galan-Rodriguez
Sep 9, 2004·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Andrea GiuffridaDaniele Piomelli
Dec 23, 2004·Journal of Pharmacological Sciences·Hiroshi Ujike, Yukitaka Morita
Apr 21, 2005·European Journal of Pharmacology·Fabrício A Moreira, Francisco S Guimarães
Apr 26, 2005·Addiction·Robert F FerdinandFrank C Verhulst
May 20, 2006·Experimental Brain Research·Kelly A NewellXu-Feng Huang
May 26, 2006·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·István KatonaTamás F Freund
Jun 2, 2006·The British Journal of Psychiatry : the Journal of Mental Science·Nicola J WilesGlyn Lewis
Jun 22, 2006·European Archives of Psychiatry and Clinical Neuroscience·Isabel Martínez-GrasGabriel Rubio
Sep 12, 2006·The Journal of Neuropsychiatry and Clinical Neurosciences·Jeremy Quickfall, David Crockford
Sep 21, 2007·Neuroscience Letters·Jürgen SeifertManfred Stuhrmann
Nov 6, 2007·The British Journal of Psychiatry : the Journal of Mental Science·Stanley ZammitMichael J Owen
Jan 11, 2008·American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics·Iván Chavarría-SilesMichael A Escamilla
Mar 1, 2008·Journal of Psychopharmacology·Stéphane PotvinEmmanuel Stip
Jun 3, 2008·The British Journal of Psychiatry : the Journal of Mental Science·Jouko MiettunenJuha Veijola
Jun 19, 2008·World Psychiatry : Official Journal of the World Psychiatric Association (WPA)·Wayne Hall, Louisa Degenhardt
Jul 2, 2008·Expert Review of Neurotherapeutics·Kirsten R Müller-Vahl, Hinderk M Emrich

❮ Previous
Next ❯

Citations

Aug 12, 2016·Molecular Neurobiology·Yousong SuDonghong Cui
Feb 22, 2017·Molecular Psychiatry·A Busquets-GarciaG Marsicano
Oct 28, 2019·EMBO Molecular Medicine·Masayuki IdeTakeo Yoshikawa
Aug 2, 2019·Current Neuropharmacology·Eric Murillo-RodríguezPablo Torterolo
Jun 15, 2017·Frontiers in Molecular Neuroscience·Eric Murillo-RodríguezGloria Arankowsky-Sandoval
Jun 27, 2019·Journal of Psychopharmacology·Carolina MuguruzaLuis F Callado
Aug 15, 2019·Neurotoxicology·Stefania BonaccorsoFabrizio Schifano
Dec 15, 2020·Biological Psychiatry : Cognitive Neuroscience and Neuroimaging·Valerie L TryonTara A Niendam
Dec 18, 2020·Frontiers in Psychiatry·Isadora L CortezFelipe V Gomes
Feb 23, 2021·Frontiers in Pharmacology·Cássio Morais LossVanessa Costhek Abílio
Aug 29, 2020·Biological Psychiatry : Cognitive Neuroscience and Neuroimaging·Erica Zamberletti, Tiziana Rubino
May 2, 2021·Pharmacology, Biochemistry, and Behavior·Jenny L WilkersonLance R McMahon
May 13, 2021·The FEBS Journal·Almudena Robledo-MenendezEdgar Soria-Gomez
Jun 17, 2020·Current Drug Targets·Hemen S Ved, Gaurav M Doshi
Dec 18, 2020·Dermatology : International Journal for Clinical and Investigative Dermatology·Hope R RietcheckRobert P Dellavalle

❮ Previous
Next ❯

Methods Mentioned

BETA
sedation
Pharmacotherapy

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Related Papers

Journal of Endocrinological Investigation
N M Kogan, R Mechoulam
Biological Psychiatry
Hiroki IshiguroTadao Arinami
Recent Patents on CNS Drug Discovery
Jana KucerovaVincenzo Micale
Frontiers in Behavioral Neuroscience
Natalia BattistaM Maccarrone
© 2022 Meta ULC. All rights reserved